Aytu Biopharma (AYTU) Non Operating Investment Income (2016 - 2017)
Aytu Biopharma's (AYTU) quarterly Non Operating Investment Income came in at -$292455.0 in Q2 2017, little changed on a QoQ basis from -$292455.0 in Q1 2017.
Aytu Biopharma (AYTU) Non Operating Investment Income (2016 - 2017) Analysis & Trends
Aytu Biopharma (AYTU) has 2 years of Non Operating Investment Income data on file, last reported at -$292455.0 in Q2 2017.
- On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to -$292455.0 in Q2 2017; TTM through Jun 2017 was -$353974.0, a N/A change from a year earlier, with the FY2017 full-year figure at -$61519.0, up 93.67% from the prior year.
- Non Operating Investment Income for Q2 2017 stood at -$292455.0, roughly flat from -$292455.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for AYTU reached as high as $728100.0 in Q3 2016 and fell as low as -$497164.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Aytu Biopharma | 21.45 Mn | -5.27 Mn | 7.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -292,455.00 |
| Jun 30, 2017 | -292,455.00 |
| Mar 31, 2017 | -292,455.00 |
| Mar 31, 2017 | -292,455.00 |
| Dec 31, 2016 | -497,164.00 |
| Dec 31, 2016 | -497,164.00 |
| Sep 30, 2016 | 728,100.00 |
| Sep 30, 2016 | 728,100.00 |